Exchange Traded Concepts LLC Has $643,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

Exchange Traded Concepts LLC reduced its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 31.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,830 shares of the company's stock after selling 6,311 shares during the quarter. Exchange Traded Concepts LLC's holdings in Twist Bioscience were worth $643,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Geode Capital Management LLC increased its holdings in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after buying an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans bought a new stake in Twist Bioscience in the third quarter worth $43,992,000. Wellington Management Group LLP boosted its holdings in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC lifted its holdings in Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company's stock worth $34,660,000 after purchasing an additional 112,272 shares during the last quarter.

Twist Bioscience Stock Up 3.4 %

Shares of TWST stock traded up $1.68 during mid-day trading on Thursday, reaching $51.20. The stock had a trading volume of 133,291 shares, compared to its average volume of 681,468. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The firm has a market cap of $3.04 billion, a PE ratio of -14.21 and a beta of 1.85. The firm's 50 day simple moving average is $48.00 and its 200 day simple moving average is $46.38.

Insider Activity

In related news, SVP Paula Green sold 1,057 shares of the firm's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the transaction, the senior vice president now owns 121,013 shares in the company, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 659 shares of the company's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the completion of the sale, the insider now owns 94,481 shares in the company, valued at $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,801 shares of company stock worth $4,147,858. Corporate insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

TWST has been the subject of several analyst reports. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. TD Cowen reiterated a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.